Show simple item record

dc.contributor.authorGottlieb, AB
dc.contributor.authorMerola, JF
dc.contributor.authorReich, K
dc.contributor.authorBehrens, F
dc.contributor.authorNash, P
dc.contributor.authorGriffiths, CEM
dc.contributor.authorBao, W
dc.contributor.authorPellet, P
dc.contributor.authorPricop, L
dc.contributor.authorMcInnes, IB
dc.date.accessioned2021-06-08T00:56:00Z
dc.date.available2021-06-08T00:56:00Z
dc.date.issued2021
dc.identifier.issn0007-0963
dc.identifier.doi10.1111/bjd.20413
dc.identifier.urihttp://hdl.handle.net/10072/404975
dc.description.abstractBACKGROUND: Secukinumab (an interleukin [IL]-17A inhibitor) has demonstrated significantly higher efficacy vs. etanercept (a tumour necrosis factor inhibitor) and ustekinumab (an IL-12/23 inhibitor) in patients with moderate to severe plaque psoriasis. OBJECTIVES: To report 52-week results from a pre-specified analysis of patients with active psoriatic arthritis (PsA) having concomitant moderate to severe plaque psoriasis from head-to-head EXCEED monotherapy study comparing secukinumab with adalimumab. METHODS: Patients were randomised to receive secukinumab 300 mg subcutaneous at baseline, Week 1-4, followed every four weeks (q4w) until Week 48 or adalimumab 40 mg subcutaneous q2w from baseline until Week 50. Assessments in patients with concomitant moderate to severe psoriasis, defined as having body surface area (BSA)>10% or Psoriasis Area and Severity Index (PASI) ≥10 at baseline included musculoskeletal, skin and quality of life outcomes. Missing data were handled using multiple imputation. RESULTS: Of the 853 patients (secukinumab [N=426], adalimumab [N=427]), 211 (24.7%) had concomitant moderate to severe psoriasis (secukinumab [N=110, 25.8%], adalimumab [N=101, 23.7%]). Up to Week 50, 5.5% patients discontinued secukinumab vs.17.8% in the adalimumab group. Proportion of patients who achieved American College of Rheumatology (ACR) 20 response was 76.4% with secukinumab vs. 68.3% with adalimumab (p=0·1752), PASI 100 response was 39.1% vs. 23.8%, (p=0.0136) and simultaneous improvement in ACR50 and PASI 100 response at Week 52 was 28.2% vs.17.7%, respectively(p=0.0604). Secukinumab demonstrated consistently higher responses vs. adalimumab across skin endpoints. CONCLUSIONS: This pre-specified analysis in PsA patients with concomitant moderate to severe plaque psoriasis in the EXCEED study provides further evidence that interleukin-17 inhibitors offer a comprehensive biologic treatment to manage the concomitant features of psoriasis and PsA.
dc.description.peerreviewedYes
dc.languageeng
dc.publisherWiley
dc.relation.ispartofjournalBritish Journal of Dermatology
dc.subject.fieldofresearchClinical sciences
dc.subject.fieldofresearchOncology and carcinogenesis
dc.subject.fieldofresearchcode3202
dc.subject.fieldofresearchcode3211
dc.titleEfficacy of secukinumab and adalimumab in psoriatic arthritis patients with concomitant moderate to severe plaque psoriasis: Results from the EXCEED, a randomised, double-blind head-to-head monotherapy study.
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationGottlieb, AB; Merola, JF; Reich, K; Behrens, F; Nash, P; Griffiths, CEM; Bao, W; Pellet, P; Pricop, L; McInnes, IB, Efficacy of secukinumab and adalimumab in psoriatic arthritis patients with concomitant moderate to severe plaque psoriasis: Results from the EXCEED, a randomised, double-blind head-to-head monotherapy study, British Journal of Dermatology, 2021
dc.date.updated2021-06-08T00:44:22Z
dc.description.versionAccepted Manuscript (AM)
gro.description.notepublicThis publication has been entered in Griffith Research Online as an advanced online version.
gro.rights.copyright© 2021 British Association of Dermatologists. This is the peer reviewed version of the following article: Efficacy of secukinumab and adalimumab in psoriatic arthritis patients with concomitant moderate to severe plaque psoriasis: Results from the EXCEED, a randomised, double-blind head-to-head monotherapy study, British Journal of Dermatology, 2021, which has been published in final form at https://doi.org/10.1111/bjd.20413. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving (http://olabout.wiley.com/WileyCDA/Section/id-828039.html)
gro.hasfulltextFull Text
gro.griffith.authorNash, Peter


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record